Table 1.

Characteristics of involved subjects at baseline

	Batroxobin, n = 21	Control, n = 10	P‐value
Demographic
Gender (Female/Male)	12/9	4/6	0.458
Age (y)	29.8 ± 14.5	39.2 ± 21.5	0.226
Clinical appearances
Coma	2 (9.5%)	0 (0.0%)	1.000
Seizures	12 (57.1%)	3 (30.0%)	0.252
Focal signs	9 (42.9%)	2 (20.0%)	0.262
Hyper‐fibrinogen condition	9 (42.9%)	0 (0.0%)	0.030
NIHSS scores at admission	0.00 (0.00, 2.00)	0.00 (0.00, 2.50)	0.539
mRS scores at admission	3.00 (2.00, 3.00)	2.00 (1.00, 4.00)	0.370
Time of hospital stay (d)	13.14 ± 2.89	11.90 ± 2.64	0.260
Time from symptom onset to admission (d)	19.84 ± 15.28	24.60 ± 20.04	0.480
Follow‐up time	132.67 ± 113.23	194.50 ± 110.58	0.163
Intracerebral hemorrhage	0 (0.0%)	1 (10.0%)	0.323
Risk factors
Pregnancy	3 (14.3%)	1 (10.0%)	1.000
Infection	3 (14.3%)	1 (10.0%)	1.000
Oral contraceptives	2 (9.5%)	0 (0.0%)	1.000
Hyperhomocysteinemia	4 (19.0%)	0 (0.0%)	0.277
Thrombophilia	9 (42.9%)	3 (30.0%)	0.697
Hematologic disorders	2 (9.5%)	3 (30.0%)	0.296
Systemic diseases	2 (9.5%)	0 (0.0%)	1.000